董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jeffrey T. Elliott | 男 | Director | 48 | 27.54万美元 | 4.30 | 2026-01-19 |
| Everett Cunningham | 男 | Director,President and Chief Executive Officer | 59 | 未披露 | 未持股 | 2026-01-19 |
| Garret Hampton | 男 | Director | 60 | 28.39万美元 | 未持股 | 2026-01-19 |
| Alan Sachs | 男 | Director | -- | 28.27万美元 | 未持股 | 2026-01-19 |
| Ivana Magovcevic Liebisch | 女 | Director | 58 | 26.12万美元 | 3.54 | 2026-01-19 |
| William P. Donnelly | 男 | Chair of the Board and Director | 64 | 59.68万美元 | 20.56 | 2026-01-19 |
| Scott Mendel | 男 | Director | 59 | 42.52万美元 | 1.23 | 2026-01-19 |
| Karen A. Flynn | 女 | Director | 63 | 27.00万美元 | 8.80 | 2026-01-19 |
| Myla P. Lai Goldman | 女 | Director | 68 | 41.28万美元 | 0.70 | 2026-01-19 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vandana Sriram | 女 | Chief Financial Officer and Treasurer | 53 | 221.22万美元 | 15.12 | 2026-01-19 |
| Everett Cunningham | 男 | Director,President and Chief Executive Officer | 59 | 未披露 | 未持股 | 2026-01-19 |
董事简历
中英对照 | 中文 | 英文- Jeffrey T. Elliott
-
JeffreyT.Elliott自2016年11月起担任我们的首席财务官。在被任命为首席财务官之前，埃利奥特先生于2016年6月至2016年11月担任公司Vice President，业务发展和战略。加入公司之前，他曾任职Robert W.Baird&Co.（从2007年到2016年），在那里他曾担任高级研究分析师，涉及诊断和生命科学工具公司。在职业生涯早期，Elliott先生曾在Walgreens担任供应链角色，并在Cap Gemini Ernst&Young担任顾问。Elliott先生在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得工商管理理学学士学位，并在芝加哥大学布斯商学院（University of Chicago Booth School of Business）获得工商管理硕士学位，是CFA特许持有人。
Jeffrey T. Elliott has served as Chief Financial Officer since November 2016. Prior to his appointment as Chief Financial Officer, Mr. Elliott served as the Company's Vice President, Business Development and Strategy, from June 2016 to November 2016. Prior to joining the Company, from 2007 to 2016 Mr. Elliott was with Robert W. Baird & Co., where from June 2012 to June 2016 he was a senior research analyst who covered diagnostics and life science tools companies. Earlier in his career, Mr. Elliott worked in a supply chain role for Walgreens and as a consultant at Cap Gemini Ernst & Young. Mr. Elliott earned a Bachelor of Science in Business Administration from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the University of Chicago Booth School of Business and is a CFA charterholder. - JeffreyT.Elliott自2016年11月起担任我们的首席财务官。在被任命为首席财务官之前，埃利奥特先生于2016年6月至2016年11月担任公司Vice President，业务发展和战略。加入公司之前，他曾任职Robert W.Baird&Co.（从2007年到2016年），在那里他曾担任高级研究分析师，涉及诊断和生命科学工具公司。在职业生涯早期，Elliott先生曾在Walgreens担任供应链角色，并在Cap Gemini Ernst&Young担任顾问。Elliott先生在伊利诺伊大学香槟分校（University of Illinois at Urbana-Champaign）获得工商管理理学学士学位，并在芝加哥大学布斯商学院（University of Chicago Booth School of Business）获得工商管理硕士学位，是CFA特许持有人。
- Jeffrey T. Elliott has served as Chief Financial Officer since November 2016. Prior to his appointment as Chief Financial Officer, Mr. Elliott served as the Company's Vice President, Business Development and Strategy, from June 2016 to November 2016. Prior to joining the Company, from 2007 to 2016 Mr. Elliott was with Robert W. Baird & Co., where from June 2012 to June 2016 he was a senior research analyst who covered diagnostics and life science tools companies. Earlier in his career, Mr. Elliott worked in a supply chain role for Walgreens and as a consultant at Cap Gemini Ernst & Young. Mr. Elliott earned a Bachelor of Science in Business Administration from the University of Illinois at Urbana-Champaign and a Master of Business Administration from the University of Chicago Booth School of Business and is a CFA charterholder.
- Everett Cunningham
-
Everett Cunningham，是依诺米那的首席商务官（CCO），负责构建、指导、管理公司的全球商业组织和商业战略。Cunningham于2024年6月加入该公司，在医疗保健技术、生命科学和制药行业拥有20多年的丰富商业经验。在加入精密科学之前，他曾在奎斯特诊疗、GE医疗集团和辉瑞担任过多个高级领导职务，在那里他花了21年时间担任多个高级领导职务。坎宁安拥有西北大学经济学学位。他是CitiWide Harm Reduction，Inc.的董事会成员，CitiWide Harm Reduction，Inc.是一家为边缘化人群提供服务的社区组织。
Everett Cunningham,is Illumina's Chief Commercial Officer (CCO), responsible for building, guiding, and managing the company's global commercial organization and commercial strategy. Cunningham joined the company in June 2024 and has more than 20 years of extensive commercial experience across healthcare tech, life sciences and pharmaceutical industries. Prior to Exact Sciences, he held various senior leadership roles at Quest Diagnostics, GE Healthcare, and Pfizer where he spent 21 years in various senior leadership roles. Cunningham has a degree in economics from Northwestern University. He is a member of the Board of Directors for CitiWide Harm Reduction, Inc., a community-based organization providing service provisions to marginalized populations. - Everett Cunningham，是依诺米那的首席商务官（CCO），负责构建、指导、管理公司的全球商业组织和商业战略。Cunningham于2024年6月加入该公司，在医疗保健技术、生命科学和制药行业拥有20多年的丰富商业经验。在加入精密科学之前，他曾在奎斯特诊疗、GE医疗集团和辉瑞担任过多个高级领导职务，在那里他花了21年时间担任多个高级领导职务。坎宁安拥有西北大学经济学学位。他是CitiWide Harm Reduction，Inc.的董事会成员，CitiWide Harm Reduction，Inc.是一家为边缘化人群提供服务的社区组织。
- Everett Cunningham,is Illumina's Chief Commercial Officer (CCO), responsible for building, guiding, and managing the company's global commercial organization and commercial strategy. Cunningham joined the company in June 2024 and has more than 20 years of extensive commercial experience across healthcare tech, life sciences and pharmaceutical industries. Prior to Exact Sciences, he held various senior leadership roles at Quest Diagnostics, GE Healthcare, and Pfizer where he spent 21 years in various senior leadership roles. Cunningham has a degree in economics from Northwestern University. He is a member of the Board of Directors for CitiWide Harm Reduction, Inc., a community-based organization providing service provisions to marginalized populations.
- Garret Hampton
-
Garret Hampton,2020年至2024年，他在赛默飞世尔，Inc.（NYSE：TMO）担任临床下一代测序和肿瘤学总裁，在那里他领导了一个800人的部门，专注于肿瘤学诊断。在此之前，他是Illumina, Inc.（NASDAQ：ILMN）临床基因组学高级副总裁，此前曾在Genentech、Celgene和诺华研究基金会基因组学研究所担任高级领导职务。现任IDEAYA生物科学，Inc.（NASDAQ：IDYA）独立董事。Hampton博士在伦敦大学学院获得遗传学博士学位，在都柏林三一学院获得自然科学、遗传学硕士和学士学位。
Garret Hampton,From 2020 to 2024, he served as President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific, Inc. (NYSE: TMO), where he led a 800-person division focused on oncology diagnostics. Prior to that, he was Senior Vice President of Clinical Genomics at Illumina, Inc. (NASDAQ: ILMN), and previously held senior leadership roles at Genentech, Celgene and the Genomics Institute of the Novartis Research Foundation. He currently serves as an independent director of IDEAYA Biosciences, Inc. (NASDAQ: IDYA). Dr. Hampton earned his Ph.D. in Genetics from University College London and his M.A. and B.S. Natural Science, Genetics, from Trinity College Dublin. - Garret Hampton,2020年至2024年，他在赛默飞世尔，Inc.（NYSE：TMO）担任临床下一代测序和肿瘤学总裁，在那里他领导了一个800人的部门，专注于肿瘤学诊断。在此之前，他是Illumina, Inc.（NASDAQ：ILMN）临床基因组学高级副总裁，此前曾在Genentech、Celgene和诺华研究基金会基因组学研究所担任高级领导职务。现任IDEAYA生物科学，Inc.（NASDAQ：IDYA）独立董事。Hampton博士在伦敦大学学院获得遗传学博士学位，在都柏林三一学院获得自然科学、遗传学硕士和学士学位。
- Garret Hampton,From 2020 to 2024, he served as President of Clinical Next Generation Sequencing and Oncology at Thermo Fisher Scientific, Inc. (NYSE: TMO), where he led a 800-person division focused on oncology diagnostics. Prior to that, he was Senior Vice President of Clinical Genomics at Illumina, Inc. (NASDAQ: ILMN), and previously held senior leadership roles at Genentech, Celgene and the Genomics Institute of the Novartis Research Foundation. He currently serves as an independent director of IDEAYA Biosciences, Inc. (NASDAQ: IDYA). Dr. Hampton earned his Ph.D. in Genetics from University College London and his M.A. and B.S. Natural Science, Genetics, from Trinity College Dublin.
- Alan Sachs
-
Alan Sachs，最近，他在赛默飞世尔（NYSE：TMO）工作了九年，2021年至2025年担任首席医疗官，2016年至2021年担任首席科学官。在这些职位上，他领导了公司的研发工作，倡导跨学科创新，并加速采用诊断平台和测试。在此之前，他曾于2012年至2016年在生命科学（前纳斯达克股票代码：LIFE）担任副总裁兼全球研发主管。在其职业生涯的早期，他于2001年至2011年在默沙东研究实验室工作了十年，负责技术开发和应用，建立并领导RNA疗法、分子分析和转化科学方面的全球部门，并管理复杂的外部合作。他的职业生涯始于大学的教员。
Alan Sachs,has more than two decades of experience in molecular diagnostics and technology development. Most recently, he spent nine years at Thermo Fisher Scientific (NYSE: TMO), serving as Chief Medical Officer from 2021 to 2025 and Chief Scientific Officer from 2016 to 2021. In those roles, he led the company's research and development efforts, championing innovation across disciplines and accelerating the adoption of diagnostic platforms and tests. Prior to that, he served as Vice President and Global Head of Research and Development at Life Technologies Corporation (formerly NASDAQ: LIFE), from 2012 to 2016. Earlier in his career, he spent a decade at Merck Research Laboratories from 2001 to 2011, where he ran technology development and application, built and led global departments in RNA therapeutics, molecular profiling and translational sciences, and managed complex external collaborations. He began his career as a faculty member at The University of California, Berkeley, where he contributed to the advancement of molecular and cellular biology. Dr. Sachs holds an M.D. and a Ph.D. in Cell Biology from Stanford University and a B.A. in Biological Sciences from Cornell University. - Alan Sachs，最近，他在赛默飞世尔（NYSE：TMO）工作了九年，2021年至2025年担任首席医疗官，2016年至2021年担任首席科学官。在这些职位上，他领导了公司的研发工作，倡导跨学科创新，并加速采用诊断平台和测试。在此之前，他曾于2012年至2016年在生命科学（前纳斯达克股票代码：LIFE）担任副总裁兼全球研发主管。在其职业生涯的早期，他于2001年至2011年在默沙东研究实验室工作了十年，负责技术开发和应用，建立并领导RNA疗法、分子分析和转化科学方面的全球部门，并管理复杂的外部合作。他的职业生涯始于大学的教员。
- Alan Sachs,has more than two decades of experience in molecular diagnostics and technology development. Most recently, he spent nine years at Thermo Fisher Scientific (NYSE: TMO), serving as Chief Medical Officer from 2021 to 2025 and Chief Scientific Officer from 2016 to 2021. In those roles, he led the company's research and development efforts, championing innovation across disciplines and accelerating the adoption of diagnostic platforms and tests. Prior to that, he served as Vice President and Global Head of Research and Development at Life Technologies Corporation (formerly NASDAQ: LIFE), from 2012 to 2016. Earlier in his career, he spent a decade at Merck Research Laboratories from 2001 to 2011, where he ran technology development and application, built and led global departments in RNA therapeutics, molecular profiling and translational sciences, and managed complex external collaborations. He began his career as a faculty member at The University of California, Berkeley, where he contributed to the advancement of molecular and cellular biology. Dr. Sachs holds an M.D. and a Ph.D. in Cell Biology from Stanford University and a B.A. in Biological Sciences from Cornell University.
- Ivana Magovcevic Liebisch
-
Ivana Magovcevic Liebisch，自2020年7月起担任Vigil Neuroscience， Inc. （Nasdaq： VIGL）（“VIGL”）的总裁兼首席执行官，并担任其董事会成员。在Vigil之前，Magovcevic Liebisch博士于2018年3月至2020年4月担任制药公司Ipsen S.A. （OTCMKTS： IPSEY）（“Ipsen”）的执行副总裁兼首席商务官，在那里她领导外部创新，业务发展和联盟管理职能。在加入Ipsen之前，Magovcevic Liebisch博士于2017年5月至2018年3月担任Axcella Health Inc. （OTC： AXL）的执行副总裁、首席战略和企业发展官，并于2013年3月至2017年5月担任Teva Pharmaceutical Industries Ltd. （NYSE： Teva）的高级副总裁、特种药物业务全球业务发展主管。Magovcevic Liebisch博士曾于2001年4月至2013年3月在Dyax Corp.（被Shire plc（“Shire”）收购，现为Takeda Pharmaceutical Company Limited（纽约证券交易所：TAK）（“Takeda”））担任管理职务，范围和责任越来越大，包括执行副总裁兼首席运营官，在那里她推出了公司的第一种药物Kalbitor用于孤儿症，遗传性血管性水肿。Magovcevic Liebisch博士在Transkaryotic Therapies， Inc.（被Shire收购，现为Takeda）开始了她的生物制药职业生涯，在那里她担任知识产权和专利顾问总监（1998年至2001年）。Magovcevic Liebisch博士目前担任Acrivon Therapeutics， Inc. （Nasdaq： ACRV）的董事。此前，她曾担任Absci Corporation （Nasdaq： ABSI）的董事会主席，并担任Aeglea BioTherapeutics， Inc.（现为Spyre Therapeutics， Inc. （Nasdaq： SYRE））和Applied Genetic Technologies Corporation（被Syncona Ltd.收购，现为Beacon Therapeutics Holdings Ltd.）的董事。Magovcevic Liebisch博士也是波士顿科学博物馆和波士顿芭蕾舞团的受托人，Beth Israel Deaconess Medical Center的监督员。她获得惠顿学院（Wheaton College）生物学和化学学士学位，哈佛大学遗传学博士学位，Suffolk大学法学院高科技法法学博士学位。
Ivana Magovcevic Liebisch,has served as President and Chief Executive Officer of Vigil Neuroscience, Inc. (Nasdaq: VIGL) ("Vigil") and as a member of their board of directors since July 2020. Prior to Vigil, Dr. Magovcevic Liebisch was Executive Vice President, Chief Business Officer at Ipsen S.A. (OTCMKTS: IPSEY) ("Ipsen"), a pharmaceutical company, from March 2018 to April 2020, where she led the External Innovation, Business Development and Alliance Management functions. Prior to Ipsen, Dr. Magovcevic Liebisch was Executive Vice President, Chief Strategy and Corporate Development Officer at Axcella Health Inc. (OTC: AXL) from May 2017 to March 2018, and Senior Vice President, Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) from March 2013 to May 2017. Dr. Magovcevic Liebisch previously worked at Dyax Corp. (acquired by Shire plc ("Shire"), now Takeda Pharmaceutical Company Limited (NYSE: TAK) ("Takeda")) from April 2001 to March 2013 in management roles of increasing scope and responsibility, including Executive Vice President and Chief Operating Officer, where she launched the company's first drug, Kalbitor for an orphan indication, hereditary angioedema. Dr. Magovcevic Liebisch began her biopharmaceutical career at Transkaryotic Therapies, Inc. (acquired by Shire, now Takeda), where she was Director of Intellectual Property and Patent Counsel from 1998 to 2001. Dr. Magovcevic Liebisch currently serves as a director of Acrivon Therapeutics, Inc. (Nasdaq: ACRV). Previously, she was the Chairperson of the board of directors of Absci Corporation (Nasdaq: ABSI) and served as a director of Aeglea BioTherapeutics, Inc. (now Spyre Therapeutics, Inc. (Nasdaq: SYRE)) and Applied Genetic Technologies Corporation (acquired by Syncona Ltd., now Beacon Therapeutics Holdings Ltd). Dr. Magovcevic Liebisch is also a trustee of the Boston Museum of Science and of the Boston Ballet, and overseer of Beth Israel Deaconess Medical Center. She received a Bachelor of Arts in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University, and a J.D. in high technology law from Suffolk University Law School. - Ivana Magovcevic Liebisch，自2020年7月起担任Vigil Neuroscience， Inc. （Nasdaq： VIGL）（“VIGL”）的总裁兼首席执行官，并担任其董事会成员。在Vigil之前，Magovcevic Liebisch博士于2018年3月至2020年4月担任制药公司Ipsen S.A. （OTCMKTS： IPSEY）（“Ipsen”）的执行副总裁兼首席商务官，在那里她领导外部创新，业务发展和联盟管理职能。在加入Ipsen之前，Magovcevic Liebisch博士于2017年5月至2018年3月担任Axcella Health Inc. （OTC： AXL）的执行副总裁、首席战略和企业发展官，并于2013年3月至2017年5月担任Teva Pharmaceutical Industries Ltd. （NYSE： Teva）的高级副总裁、特种药物业务全球业务发展主管。Magovcevic Liebisch博士曾于2001年4月至2013年3月在Dyax Corp.（被Shire plc（“Shire”）收购，现为Takeda Pharmaceutical Company Limited（纽约证券交易所：TAK）（“Takeda”））担任管理职务，范围和责任越来越大，包括执行副总裁兼首席运营官，在那里她推出了公司的第一种药物Kalbitor用于孤儿症，遗传性血管性水肿。Magovcevic Liebisch博士在Transkaryotic Therapies， Inc.（被Shire收购，现为Takeda）开始了她的生物制药职业生涯，在那里她担任知识产权和专利顾问总监（1998年至2001年）。Magovcevic Liebisch博士目前担任Acrivon Therapeutics， Inc. （Nasdaq： ACRV）的董事。此前，她曾担任Absci Corporation （Nasdaq： ABSI）的董事会主席，并担任Aeglea BioTherapeutics， Inc.（现为Spyre Therapeutics， Inc. （Nasdaq： SYRE））和Applied Genetic Technologies Corporation（被Syncona Ltd.收购，现为Beacon Therapeutics Holdings Ltd.）的董事。Magovcevic Liebisch博士也是波士顿科学博物馆和波士顿芭蕾舞团的受托人，Beth Israel Deaconess Medical Center的监督员。她获得惠顿学院（Wheaton College）生物学和化学学士学位，哈佛大学遗传学博士学位，Suffolk大学法学院高科技法法学博士学位。
- Ivana Magovcevic Liebisch,has served as President and Chief Executive Officer of Vigil Neuroscience, Inc. (Nasdaq: VIGL) ("Vigil") and as a member of their board of directors since July 2020. Prior to Vigil, Dr. Magovcevic Liebisch was Executive Vice President, Chief Business Officer at Ipsen S.A. (OTCMKTS: IPSEY) ("Ipsen"), a pharmaceutical company, from March 2018 to April 2020, where she led the External Innovation, Business Development and Alliance Management functions. Prior to Ipsen, Dr. Magovcevic Liebisch was Executive Vice President, Chief Strategy and Corporate Development Officer at Axcella Health Inc. (OTC: AXL) from May 2017 to March 2018, and Senior Vice President, Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) from March 2013 to May 2017. Dr. Magovcevic Liebisch previously worked at Dyax Corp. (acquired by Shire plc ("Shire"), now Takeda Pharmaceutical Company Limited (NYSE: TAK) ("Takeda")) from April 2001 to March 2013 in management roles of increasing scope and responsibility, including Executive Vice President and Chief Operating Officer, where she launched the company's first drug, Kalbitor for an orphan indication, hereditary angioedema. Dr. Magovcevic Liebisch began her biopharmaceutical career at Transkaryotic Therapies, Inc. (acquired by Shire, now Takeda), where she was Director of Intellectual Property and Patent Counsel from 1998 to 2001. Dr. Magovcevic Liebisch currently serves as a director of Acrivon Therapeutics, Inc. (Nasdaq: ACRV). Previously, she was the Chairperson of the board of directors of Absci Corporation (Nasdaq: ABSI) and served as a director of Aeglea BioTherapeutics, Inc. (now Spyre Therapeutics, Inc. (Nasdaq: SYRE)) and Applied Genetic Technologies Corporation (acquired by Syncona Ltd., now Beacon Therapeutics Holdings Ltd). Dr. Magovcevic Liebisch is also a trustee of the Boston Museum of Science and of the Boston Ballet, and overseer of Beth Israel Deaconess Medical Center. She received a Bachelor of Arts in biology and chemistry from Wheaton College, a Ph.D. in genetics from Harvard University, and a J.D. in high technology law from Suffolk University Law School.
- William P. Donnelly
-
William P. Donnelly，自2023年起担任罗派斯集团有限公司独立董事，并担任审计委员会、高管薪酬和管理发展委员会成员。唐纳利先生于2014年至2018年退休期间担任Mettler-Toledo International Inc.的执行副总裁，该公司是全球领先的精密仪器制造商，为T. Rowe Price Group, Inc. e在实验室和制造领域提供精密仪器和服务。1997年至2002年以及2004年至2014年，Donnelly先生担任Mettler-Toledo的首席财务官。2002年至2004年，担任Mettler-Toledo产品检验和某些实验室业务的部门主管。1993年至1997年，Donnelly先生曾在Elsag Bailey Process Automation，NV担任多个高级财务职务，包括首席财务官，在此之前，他于1983年至1993年在普华永道会计师事务所担任审计师。Donnelly先生获得了John Carroll大学工商管理学士学位。Donnelly是英格索兰公司的首席独立董事和董事会成员，他还担任提名和公司治理委员会主席以及审计委员会成员。他还是Quanterix Corporation的董事会成员以及审计和薪酬委员会成员。
William P. Donnelly has been a member of Ingersoll Rand Inc.'s Board of Directors since May 2017 and was appointed Lead Director in November 2021. Mr. Donnelly joined Mettler Toledo International Inc. in 1997 and from 2014 until his retirement in December 2018, was its executive vice president responsible for finance, investor relations, supply chain and information technology. From 1997 to 2002 and from 2004 to 2014 Mr. Donnelly served as Mettler Toledo's chief financial officer. From 2002 to 2004, he served as division head of Mettler Toledo's product inspection and certain lab businesses. From 1993 to 1997, Mr. Donnelly served in various senior financial roles, including chief financial officer, of Elsag Bailey Process Automation, NV and prior to that, he was an auditor with PricewaterhouseCoopers LLP from 1983 to 1993. Mr. Donnelly currently serves as the Chairman of the board of directors of Quanterix Corporation and as a member of the board of directors of T. Rowe Price Group, Inc. Mr. Donnelly received a bachelor of science in business administration from John Carroll University. - William P. Donnelly，自2023年起担任罗派斯集团有限公司独立董事，并担任审计委员会、高管薪酬和管理发展委员会成员。唐纳利先生于2014年至2018年退休期间担任Mettler-Toledo International Inc.的执行副总裁，该公司是全球领先的精密仪器制造商，为T. Rowe Price Group, Inc. e在实验室和制造领域提供精密仪器和服务。1997年至2002年以及2004年至2014年，Donnelly先生担任Mettler-Toledo的首席财务官。2002年至2004年，担任Mettler-Toledo产品检验和某些实验室业务的部门主管。1993年至1997年，Donnelly先生曾在Elsag Bailey Process Automation，NV担任多个高级财务职务，包括首席财务官，在此之前，他于1983年至1993年在普华永道会计师事务所担任审计师。Donnelly先生获得了John Carroll大学工商管理学士学位。Donnelly是英格索兰公司的首席独立董事和董事会成员，他还担任提名和公司治理委员会主席以及审计委员会成员。他还是Quanterix Corporation的董事会成员以及审计和薪酬委员会成员。
- William P. Donnelly has been a member of Ingersoll Rand Inc.'s Board of Directors since May 2017 and was appointed Lead Director in November 2021. Mr. Donnelly joined Mettler Toledo International Inc. in 1997 and from 2014 until his retirement in December 2018, was its executive vice president responsible for finance, investor relations, supply chain and information technology. From 1997 to 2002 and from 2004 to 2014 Mr. Donnelly served as Mettler Toledo's chief financial officer. From 2002 to 2004, he served as division head of Mettler Toledo's product inspection and certain lab businesses. From 1993 to 1997, Mr. Donnelly served in various senior financial roles, including chief financial officer, of Elsag Bailey Process Automation, NV and prior to that, he was an auditor with PricewaterhouseCoopers LLP from 1983 to 1993. Mr. Donnelly currently serves as the Chairman of the board of directors of Quanterix Corporation and as a member of the board of directors of T. Rowe Price Group, Inc. Mr. Donnelly received a bachelor of science in business administration from John Carroll University.
- Scott Mendel
-
Scott Mendel，2014年5月起，担任本公司的首席财务官。加入本公司之前，2010年3月起，他担任The Active Network, Inc.的首席财务官，这是全球性的软件即服务公司，为事件活动组织者提供相关技术，直到2013年12月该公司被私募股权公司Vista Equity Partners收购。加入The Active Network, Inc.之前，他在多元化的技术、媒体及金融服务公司General Electric，担任了20多年的财务职位，其中包括在2003年3月至2010年3月期间，担任其卫生保健信息技术部的首席财务官，这是医疗技术及服务的顶尖提供商。他在 Indiana University获得财务学士学位，在Northwestern University's Kellogg School of Management获得工商管理硕士学位。
Scott Mendel has served as Chief Financial Officer of the Company since May 2014. Prior to joining the Company, Mr. Mendel served as the Chief Financial Officer of The Active Network, Inc., a global software as a service SaaS company that provides technology to organizers of events and activities, from March 2010 through its acquisition by the private-equity firm Vista Equity Partners in December 2013. Prior to joining The Active Network, Mr. Mendel held finance positions at General Electric, a diversified technology, media and financial services company, for over 20 years, including chief financial officer from March 2003 to March 2010 for General Electric’s Healthcare IT division, a leading provider of medical technologies and services. Mr. Mendel earned a B.S. in finance from Indiana University and an M.B.A. from Northwestern University’s Kellogg School of Management. - Scott Mendel，2014年5月起，担任本公司的首席财务官。加入本公司之前，2010年3月起，他担任The Active Network, Inc.的首席财务官，这是全球性的软件即服务公司，为事件活动组织者提供相关技术，直到2013年12月该公司被私募股权公司Vista Equity Partners收购。加入The Active Network, Inc.之前，他在多元化的技术、媒体及金融服务公司General Electric，担任了20多年的财务职位，其中包括在2003年3月至2010年3月期间，担任其卫生保健信息技术部的首席财务官，这是医疗技术及服务的顶尖提供商。他在 Indiana University获得财务学士学位，在Northwestern University's Kellogg School of Management获得工商管理硕士学位。
- Scott Mendel has served as Chief Financial Officer of the Company since May 2014. Prior to joining the Company, Mr. Mendel served as the Chief Financial Officer of The Active Network, Inc., a global software as a service SaaS company that provides technology to organizers of events and activities, from March 2010 through its acquisition by the private-equity firm Vista Equity Partners in December 2013. Prior to joining The Active Network, Mr. Mendel held finance positions at General Electric, a diversified technology, media and financial services company, for over 20 years, including chief financial officer from March 2003 to March 2010 for General Electric’s Healthcare IT division, a leading provider of medical technologies and services. Mr. Mendel earned a B.S. in finance from Indiana University and an M.B.A. from Northwestern University’s Kellogg School of Management.
- Karen A. Flynn
-
Karen A. Flynn，2012年6月起担任Pharmaceutical Packaging Systems美洲区总裁。2008年5月至2012年6月，她担任销售副总裁。2000至2008年，她在销售管理部门工作，最近一职是担任Catalent（前 Cardinal Health）的全球会计副总裁。此前，她在West担任多个职位，包括品质、研发和销售等部门。
Karen A. Flynn,has served as a member of Quanterix Corporation Board since June 2022. Ms. Flynn retired from her position as Chief Commercial Officer of Catalent, Inc. (NYSE: CTLT) ("Catalent") in September 2022. Ms. Flynn previously served Catalent as President, Biologics and Chief Commercial Officer from January 2020 to October 2021. After retirement, Ms. Flynn served on an interim basis as Catalent's President, Biomodalities from April 2023 to October 2023. Prior to joining Catalent, Ms. Flynn served as the Senior Vice President and Chief Commercial Officer of West Pharmaceutical Services, Inc. (NYSE: WST) ("West Pharmaceutical") from 2016 to 2019, having previously served as the company's President, Pharmaceutical Packaging Systems since 2014. Ms. Flynn has served as a director of Sotera Health Company (Nasdaq: SHC) since November 2023 and Stevanato Group S.p.A. (NYSE: STVN) since May 2024. She also is a member of the Board of Trustees of The Franklin Institute and serves in the Hesburgh Women of Impact mentorship program for the University of Notre Dame. Ms. Flynn is also a director of GermFree Laboratories, Inc. and of Ascend Advanced Therapies Ltd. Previously, Ms. Flynn served as a director of Catalent from September 2022 to January 2024 and Recro Pharma, Inc. from September 2015 to January 2020. Ms. Flynn holds a Master of Science in business administration from Boston University, a master of science in engineering from the University of Pennsylvania and a Bachelor of Science in pre-professional studies from the University of Notre Dame. - Karen A. Flynn，2012年6月起担任Pharmaceutical Packaging Systems美洲区总裁。2008年5月至2012年6月，她担任销售副总裁。2000至2008年，她在销售管理部门工作，最近一职是担任Catalent（前 Cardinal Health）的全球会计副总裁。此前，她在West担任多个职位，包括品质、研发和销售等部门。
- Karen A. Flynn,has served as a member of Quanterix Corporation Board since June 2022. Ms. Flynn retired from her position as Chief Commercial Officer of Catalent, Inc. (NYSE: CTLT) ("Catalent") in September 2022. Ms. Flynn previously served Catalent as President, Biologics and Chief Commercial Officer from January 2020 to October 2021. After retirement, Ms. Flynn served on an interim basis as Catalent's President, Biomodalities from April 2023 to October 2023. Prior to joining Catalent, Ms. Flynn served as the Senior Vice President and Chief Commercial Officer of West Pharmaceutical Services, Inc. (NYSE: WST) ("West Pharmaceutical") from 2016 to 2019, having previously served as the company's President, Pharmaceutical Packaging Systems since 2014. Ms. Flynn has served as a director of Sotera Health Company (Nasdaq: SHC) since November 2023 and Stevanato Group S.p.A. (NYSE: STVN) since May 2024. She also is a member of the Board of Trustees of The Franklin Institute and serves in the Hesburgh Women of Impact mentorship program for the University of Notre Dame. Ms. Flynn is also a director of GermFree Laboratories, Inc. and of Ascend Advanced Therapies Ltd. Previously, Ms. Flynn served as a director of Catalent from September 2022 to January 2024 and Recro Pharma, Inc. from September 2015 to January 2020. Ms. Flynn holds a Master of Science in business administration from Boston University, a master of science in engineering from the University of Pennsylvania and a Bachelor of Science in pre-professional studies from the University of Notre Dame.
- Myla P. Lai Goldman
-
Myla P. Lai Goldman，自2025年7月起担任Quanterix Corporation董事会成员。她于2021年9月至2025年7月担任Akoya董事会成员。Lai-Goldman博士是精准医疗公司GeneCentric Therapeutics，Inc.的董事长，她是该公司的联合创始人，此前自2011年6月起担任首席执行官兼总裁。她还是Personalized Science，LLC的管理合伙人，这是一家她于2008年创立的临床诊断咨询公司。此外，Lai-Goldman博士是Hatteras Venture Partners的风险投资合伙人，该公司是一家专注于生物制药、医疗设备、诊断和人类医学相关机会的风险投资公司。此前，Lai-Goldman博士是CancerGuide Diagnostics，Inc.（“CancerGuide Diagnostics”）的首席执行官和首席科学官。在加入CancerGuide Diagnostics之前，她曾在Laboratory Corporation of America Holdings（NYSE：LH）（“徕博科”）及其前身公司Roche Biomedical Laboratories，Inc.（OTCMKTS：RHHBY）担任过各种职务，包括执行副总裁、首席医疗官和首席科学官。Lai-Goldman博士自2014年起担任上市制药公司West Pharmaceutical（NYSE：WST）的董事，自2022年起担任NovoPath Inc.的董事，自2023年起担任Mercy BioAnalytics，Inc.的董事。Lai-Goldman博士在徕博科工作了超过18年，曾在徕博科的执行和管理委员会任职，负责三个由700多人组成的主要基因组实验室的战略和运营职责。在徕博科任职期间，她领导了所有的临床、科学和医疗活动，包括引入了400多种临床试验。她的经验包括发展合作伙伴关系、许可和收购。Dr.Lai-Goldman拥有宾夕法尼亚大学生态学专业的生物学文学学士学位，以及哥伦比亚大学Vagelos内科医生和外科医生学院的医学博士学位。
Myla P. Lai Goldman has to the Board expansive healthcare indtry experience through her senior leadership roles at GeneCentric Therapeutics (2011–present), Labcorp (1990–2008) and Roche Biomedical. She is also managing partner of Personalized Science, LLC, a clinical diagnostic consulting company that she founded in 2008. - Myla P. Lai Goldman，自2025年7月起担任Quanterix Corporation董事会成员。她于2021年9月至2025年7月担任Akoya董事会成员。Lai-Goldman博士是精准医疗公司GeneCentric Therapeutics，Inc.的董事长，她是该公司的联合创始人，此前自2011年6月起担任首席执行官兼总裁。她还是Personalized Science，LLC的管理合伙人，这是一家她于2008年创立的临床诊断咨询公司。此外，Lai-Goldman博士是Hatteras Venture Partners的风险投资合伙人，该公司是一家专注于生物制药、医疗设备、诊断和人类医学相关机会的风险投资公司。此前，Lai-Goldman博士是CancerGuide Diagnostics，Inc.（“CancerGuide Diagnostics”）的首席执行官和首席科学官。在加入CancerGuide Diagnostics之前，她曾在Laboratory Corporation of America Holdings（NYSE：LH）（“徕博科”）及其前身公司Roche Biomedical Laboratories，Inc.（OTCMKTS：RHHBY）担任过各种职务，包括执行副总裁、首席医疗官和首席科学官。Lai-Goldman博士自2014年起担任上市制药公司West Pharmaceutical（NYSE：WST）的董事，自2022年起担任NovoPath Inc.的董事，自2023年起担任Mercy BioAnalytics，Inc.的董事。Lai-Goldman博士在徕博科工作了超过18年，曾在徕博科的执行和管理委员会任职，负责三个由700多人组成的主要基因组实验室的战略和运营职责。在徕博科任职期间，她领导了所有的临床、科学和医疗活动，包括引入了400多种临床试验。她的经验包括发展合作伙伴关系、许可和收购。Dr.Lai-Goldman拥有宾夕法尼亚大学生态学专业的生物学文学学士学位，以及哥伦比亚大学Vagelos内科医生和外科医生学院的医学博士学位。
- Myla P. Lai Goldman has to the Board expansive healthcare indtry experience through her senior leadership roles at GeneCentric Therapeutics (2011–present), Labcorp (1990–2008) and Roche Biomedical. She is also managing partner of Personalized Science, LLC, a clinical diagnostic consulting company that she founded in 2008.
高管简历
中英对照 | 中文 | 英文- Vandana Sriram
Vandana Sriram于2021年9月加入Azenta生命科学，于2022年11月被任命为财务高级副总裁、公司财务总监兼首席会计官，负责监督财务会计、规划、报告和控制的所有领域。在加入公司之前，Sriram女士在通用电气工作了20多年，最近担任FP & A航空部门的负责人。她还曾担任GE Additive的首席财务官、GE Aviation的全球财务总监以及GE中东、北非和土耳其地区的FP & A负责人。在加入通用电气之前，她在安达信从事了5年的公共会计工作。
Vandana Sriram joined Azenta Life Sciences in September 2021 and was appointed as Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer in November 2022 and is responsible for oversight of all areas of financial accounting, planning, reporting and controls.Prior to joining the Company, Ms. Sriram worked for over 20 years at General Electric where she most recently was the leader of FP&A in their Aviation division. She also held roles as Chief Financial Officer for GE Additive, Global Controller for GE Aviation, and the FP&A leader for GE's Middle East, North Africa, and Turkey region. Prior to GE, she spent 5 years in public accounting at Arthur Andersen.- Vandana Sriram于2021年9月加入Azenta生命科学，于2022年11月被任命为财务高级副总裁、公司财务总监兼首席会计官，负责监督财务会计、规划、报告和控制的所有领域。在加入公司之前，Sriram女士在通用电气工作了20多年，最近担任FP & A航空部门的负责人。她还曾担任GE Additive的首席财务官、GE Aviation的全球财务总监以及GE中东、北非和土耳其地区的FP & A负责人。在加入通用电气之前，她在安达信从事了5年的公共会计工作。
- Vandana Sriram joined Azenta Life Sciences in September 2021 and was appointed as Senior Vice President of Finance, Corporate Controller and Principal Accounting Officer in November 2022 and is responsible for oversight of all areas of financial accounting, planning, reporting and controls.Prior to joining the Company, Ms. Sriram worked for over 20 years at General Electric where she most recently was the leader of FP&A in their Aviation division. She also held roles as Chief Financial Officer for GE Additive, Global Controller for GE Aviation, and the FP&A leader for GE's Middle East, North Africa, and Turkey region. Prior to GE, she spent 5 years in public accounting at Arthur Andersen.
- Everett Cunningham
Everett Cunningham，是依诺米那的首席商务官（CCO），负责构建、指导、管理公司的全球商业组织和商业战略。Cunningham于2024年6月加入该公司，在医疗保健技术、生命科学和制药行业拥有20多年的丰富商业经验。在加入精密科学之前，他曾在奎斯特诊疗、GE医疗集团和辉瑞担任过多个高级领导职务，在那里他花了21年时间担任多个高级领导职务。坎宁安拥有西北大学经济学学位。他是CitiWide Harm Reduction，Inc.的董事会成员，CitiWide Harm Reduction，Inc.是一家为边缘化人群提供服务的社区组织。
Everett Cunningham,is Illumina's Chief Commercial Officer (CCO), responsible for building, guiding, and managing the company's global commercial organization and commercial strategy. Cunningham joined the company in June 2024 and has more than 20 years of extensive commercial experience across healthcare tech, life sciences and pharmaceutical industries. Prior to Exact Sciences, he held various senior leadership roles at Quest Diagnostics, GE Healthcare, and Pfizer where he spent 21 years in various senior leadership roles. Cunningham has a degree in economics from Northwestern University. He is a member of the Board of Directors for CitiWide Harm Reduction, Inc., a community-based organization providing service provisions to marginalized populations.- Everett Cunningham，是依诺米那的首席商务官（CCO），负责构建、指导、管理公司的全球商业组织和商业战略。Cunningham于2024年6月加入该公司，在医疗保健技术、生命科学和制药行业拥有20多年的丰富商业经验。在加入精密科学之前，他曾在奎斯特诊疗、GE医疗集团和辉瑞担任过多个高级领导职务，在那里他花了21年时间担任多个高级领导职务。坎宁安拥有西北大学经济学学位。他是CitiWide Harm Reduction，Inc.的董事会成员，CitiWide Harm Reduction，Inc.是一家为边缘化人群提供服务的社区组织。
- Everett Cunningham,is Illumina's Chief Commercial Officer (CCO), responsible for building, guiding, and managing the company's global commercial organization and commercial strategy. Cunningham joined the company in June 2024 and has more than 20 years of extensive commercial experience across healthcare tech, life sciences and pharmaceutical industries. Prior to Exact Sciences, he held various senior leadership roles at Quest Diagnostics, GE Healthcare, and Pfizer where he spent 21 years in various senior leadership roles. Cunningham has a degree in economics from Northwestern University. He is a member of the Board of Directors for CitiWide Harm Reduction, Inc., a community-based organization providing service provisions to marginalized populations.